Neurimmune Revenue and Competitors
Estimated Revenue & Valuation
- Neurimmune's estimated annual revenue is currently $16.1M per year.
- Neurimmune's estimated revenue per employee is $201,000
Employee Data
- Neurimmune has 80 Employees.
- Neurimmune grew their employee count by -7% last year.
Neurimmune's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Scientific Officer | Reveal Email/Phone |
2 | Group CFO | Reveal Email/Phone |
3 | Chief Medical Officer | Reveal Email/Phone |
4 | Senior Director Program Management and Operations | Reveal Email/Phone |
5 | Associate Director | Reveal Email/Phone |
6 | Associate Director | Reveal Email/Phone |
7 | Research Associate | Reveal Email/Phone |
8 | Research Associate I | Reveal Email/Phone |
9 | Research Associate | Reveal Email/Phone |
10 | Scientist Project Lead | Reveal Email/Phone |
Neurimmune Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $53.7M | 267 | 16% | N/A | N/A |
#2 | $53.1M | 264 | 21% | N/A | N/A |
#3 | $69.1M | 344 | 26% | N/A | N/A |
#4 | $22.1M | 110 | -10% | N/A | N/A |
#5 | $151.8M | 755 | 11% | N/A | N/A |
#6 | $63.9M | 318 | 13% | N/A | N/A |
#7 | $29.9M | 149 | 13% | N/A | N/A |
#8 | $1.7M | 17 | -6% | $114.3M | N/A |
#9 | $6.8M | 34 | -6% | N/A | N/A |
#10 | $12.5M | 62 | -9% | N/A | N/A |
What Is Neurimmune?
Neurimmune is a biopharmaceutical company translating human immune memory into antibody therapeutics. Neurimmune discovered aducanumab for Alzheimer's disease together with a team of researchers at the University of Zurich and licensed it to Biogen. Neurimmune's Reverse Translational Medicine technology platform translates the genetic information from human white blood cells into selective high-affinity antibody drug candidates. Besides aducanumab, Neurimmune discovered cinpanemab for Parkinson's disease, the anti-tau antibody BIIB076 for Alzheimer's disease, the anti-miSOD1 antibody AP-101 for amyotrophic lateral sclerosis, and the anti-ATTR antibody NI006 for cardiomyopathy. These programs are currently evaluated in clinical trials.
keywords:N/A
N/A
Total Funding
80
Number of Employees
$16.1M
Revenue (est)
-7%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Schlieren
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $12.9M | 86 | -1% | N/A |
#2 | $12.9M | 86 | -1% | N/A |
#3 | $19.3M | 92 | 39% | N/A |
#4 | $15.3M | 99 | 29% | N/A |
#5 | $14M | 100 | 11% | N/A |